U.S. Markets close in 3 hrs 54 mins

VALNEVA Announces a New Research Agreement and Transfer of an Existing Commercial Agreement to Emergent BioSolutions for the Development of Vaccines in the EB66® Cell Line

Valneva Announces a New Research Agreement and Transfer of an Existing Commercial Agreement to Emergent BioSolutions for the Development of Vaccines in the EB66® Cell Line

Lyon (France), March 7, 2014 - European biotechnology company Valneva SE (Valneva) announced today that it has signed a new research license agreement and transferred an existing commercial agreement to Emergent BioSolutions Inc. (EBS), to develop new vaccines using Valneva`s EB66® cell line.

To read the full press release, please click on the following icone:

Valneva annonce un nouvel accord de recherche avec Emergent BioSolutions et un transfert d`accord commercial pour le développement de vaccins sur sa lignée cellulaire EB66®

Lyon (France), 7 mars 2014 - La société de biotechnologie européenne Valneva SE (Valneva) annonce aujourd`hui la signature d`un nouvel accord de recherche avec Emergent BioSolutions Inc. (EBS), ainsi que le transfert d`un accord commercial existant, pour le développement de vaccins sur sa lignée cellulaire EB66®.

Pour télécharger l`intégralité du communiqué, cliquez sur l`icone suivante:

  2014-03-07 Valneva Emergent PR EN
2014-03-07 Valneva Emergent PR FR


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VALNEVA via GlobeNewswire

HUG#1766974